- Home
- GMAB vs EXEL Comparison
GMAB vs EXEL Comparison
Compare GMAB & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- EXEL
- Stock Information
- Founded
- GMAB 1999
- EXEL 1994
- Country
- GMAB Denmark
- EXEL United States
- Employees
- GMAB N/A
- EXEL N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GMAB Health Care
- EXEL Health Care
- Exchange
- GMAB Nasdaq
- EXEL Nasdaq
- Market Cap
- GMAB 13.7B
- EXEL 12.0B
- IPO Year
- GMAB N/A
- EXEL 2000
- Fundamental
- Price
- GMAB $21.45
- EXEL $44.86
- Analyst Decision
- GMAB Buy
- EXEL Buy
- Analyst Count
- GMAB 8
- EXEL 18
- Target Price
- GMAB $37.80
- EXEL $43.65
- AVG Volume (30 Days)
- GMAB 1.6M
- EXEL 3.7M
- Earning Date
- GMAB 08-07-2025
- EXEL 08-05-2025
- Dividend Yield
- GMAB N/A
- EXEL N/A
- EPS Growth
- GMAB 276.80
- EXEL 237.58
- EPS
- GMAB 18.36
- EXEL 2.20
- Revenue
- GMAB $3,230,902,140.00
- EXEL $2,298,922,000.00
- Revenue This Year
- GMAB $747.74
- EXEL $9.37
- Revenue Next Year
- GMAB $14.81
- EXEL $11.05
- P/E Ratio
- GMAB $11.66
- EXEL $20.36
- Revenue Growth
- GMAB 25.43
- EXEL 24.49
- 52 Week Low
- GMAB $17.24
- EXEL $22.13
- 52 Week High
- GMAB $28.56
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- GMAB 53.47
- EXEL 56.79
- Support Level
- GMAB $20.23
- EXEL $43.21
- Resistance Level
- GMAB $21.90
- EXEL $48.74
- Average True Range (ATR)
- GMAB 0.35
- EXEL 2.01
- MACD
- GMAB 0.06
- EXEL 0.05
- Stochastic Oscillator
- GMAB 73.52
- EXEL 31.61
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.